FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891460256> ?p ?o ?g. }

• W2891460256 endingPage "1523" @default.
• W2891460256 startingPage "1511" @default.
• W2891460256 abstract "Abstract We developed a screening assay in which luciferized ID8 expressing OVA was cocultured with transgenic CD8+ T cells specifically recognizing the model antigen in an H-2b–restricted manner. The assay was screened with a small-molecule library to identify compounds that inhibit or enhance T cell–mediated killing of tumor cells. Erlotinib, an EGFR inhibitor, was the top compound that enhanced T-cell killing of tumor cells. Subsequent experiments with erlotinib and additional EGFR inhibitors validated the screen results. EGFR inhibitors increased both basal and IFNγ-induced MHC class-I presentation, which enhanced recognition and lysis of tumor cell targets by CD8+ cytotoxic T lymphocytes. The ID8 cell line was also transduced to constitutively express Cas9, and a pooled CRISPR screen, utilizing the same target tumor cell/T-cell assay, identified single-guide (sg)RNAs targeting EGFR that sensitized tumor cells to T cell–mediated killing. Combination of PD-1 blockade with EGFR inhibition showed significant synergistic efficacy in a syngeneic model, further validating EGFR inhibitors as immunomodulatory agents that enhance checkpoint blockade. This assay can be screened in high-throughput with small-molecule libraries and genome-wide CRISPR/Cas9 libraries to identify both compounds and target genes, respectively, that enhance or inhibit T-cell recognition and killing of tumor cells. Retrospective analyses of squamous-cell head and neck cancer (SCCHN) patients treated with the combination of afatinib and pembrolizumab demonstrated a rate of clinical activity exceeding that of each single agent. Prospective clinical trials evaluating the combination of an EGFR inhibitor and PD-1 blockade should be conducted." @default.
• W2891460256 created "2018-09-27" @default.
• W2891460256 creator A5002712425 @default.
• W2891460256 creator A5010627409 @default.
• W2891460256 creator A5011936892 @default.
• W2891460256 creator A5022352605 @default.
• W2891460256 creator A5032059500 @default.
• W2891460256 creator A5034758372 @default.
• W2891460256 creator A5046062147 @default.
• W2891460256 creator A5048675362 @default.
• W2891460256 creator A5051597781 @default.
• W2891460256 creator A5052329487 @default.
• W2891460256 creator A5055988161 @default.
• W2891460256 creator A5059677207 @default.
• W2891460256 creator A5060353514 @default.
• W2891460256 creator A5069427384 @default.
• W2891460256 creator A5072719557 @default.
• W2891460256 creator A5075910579 @default.
• W2891460256 creator A5076438797 @default.
• W2891460256 creator A5085278950 @default.
• W2891460256 creator A5088443977 @default.
• W2891460256 date "2018-12-01" @default.
• W2891460256 modified "2023-10-17" @default.
• W2891460256 title "A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing" @default.
• W2891460256 cites W1915043848 @default.
• W2891460256 cites W1959677146 @default.
• W2891460256 cites W1974608253 @default.
• W2891460256 cites W1979811833 @default.
• W2891460256 cites W1985928174 @default.
• W2891460256 cites W2006540387 @default.
• W2891460256 cites W2006709656 @default.
• W2891460256 cites W2015634560 @default.
• W2891460256 cites W2023994677 @default.
• W2891460256 cites W2032019019 @default.
• W2891460256 cites W2052727153 @default.
• W2891460256 cites W2068412287 @default.
• W2891460256 cites W2071217673 @default.
• W2891460256 cites W2076056217 @default.
• W2891460256 cites W2088270805 @default.
• W2891460256 cites W2088540000 @default.
• W2891460256 cites W2093137770 @default.
• W2891460256 cites W2097995306 @default.
• W2891460256 cites W2098414192 @default.
• W2891460256 cites W2123363005 @default.
• W2891460256 cites W2123918574 @default.
• W2891460256 cites W2128758225 @default.
• W2891460256 cites W2136799969 @default.
• W2891460256 cites W2138297714 @default.
• W2891460256 cites W2142022669 @default.
• W2891460256 cites W2143488876 @default.
• W2891460256 cites W2150090751 @default.
• W2891460256 cites W2166084034 @default.
• W2891460256 cites W2166662937 @default.
• W2891460256 cites W2175265591 @default.
• W2891460256 cites W2203636072 @default.
• W2891460256 cites W2221432805 @default.
• W2891460256 cites W2222086386 @default.
• W2891460256 cites W2341586961 @default.
• W2891460256 cites W2504623699 @default.
• W2891460256 cites W2518412322 @default.
• W2891460256 cites W2529484692 @default.
• W2891460256 cites W2559804019 @default.
• W2891460256 cites W2572174216 @default.
• W2891460256 cites W2736476343 @default.
• W2891460256 cites W2744743363 @default.
• W2891460256 cites W2782124401 @default.
• W2891460256 doi "https://doi.org/10.1158/2326-6066.cir-18-0193" @default.
• W2891460256 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6601346" @default.
• W2891460256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30242021" @default.
• W2891460256 hasPublicationYear "2018" @default.
• W2891460256 type Work @default.
• W2891460256 sameAs 2891460256 @default.
• W2891460256 citedByCount "53" @default.
• W2891460256 countsByYear W28914602562019 @default.
• W2891460256 countsByYear W28914602562020 @default.
• W2891460256 countsByYear W28914602562021 @default.
• W2891460256 countsByYear W28914602562022 @default.
• W2891460256 countsByYear W28914602562023 @default.
• W2891460256 crossrefType "journal-article" @default.
• W2891460256 hasAuthorship W2891460256A5002712425 @default.
• W2891460256 hasAuthorship W2891460256A5010627409 @default.
• W2891460256 hasAuthorship W2891460256A5011936892 @default.
• W2891460256 hasAuthorship W2891460256A5022352605 @default.
• W2891460256 hasAuthorship W2891460256A5032059500 @default.
• W2891460256 hasAuthorship W2891460256A5034758372 @default.
• W2891460256 hasAuthorship W2891460256A5046062147 @default.
• W2891460256 hasAuthorship W2891460256A5048675362 @default.
• W2891460256 hasAuthorship W2891460256A5051597781 @default.
• W2891460256 hasAuthorship W2891460256A5052329487 @default.
• W2891460256 hasAuthorship W2891460256A5055988161 @default.
• W2891460256 hasAuthorship W2891460256A5059677207 @default.
• W2891460256 hasAuthorship W2891460256A5060353514 @default.
• W2891460256 hasAuthorship W2891460256A5069427384 @default.
• W2891460256 hasAuthorship W2891460256A5072719557 @default.
• W2891460256 hasAuthorship W2891460256A5075910579 @default.
• W2891460256 hasAuthorship W2891460256A5076438797 @default.
• W2891460256 hasAuthorship W2891460256A5085278950 @default.
• W2891460256 hasAuthorship W2891460256A5088443977 @default.

• next